Back to Search Start Over

Tenapanor administration and the activity of the H + -coupled transporter PepT1 in healthy volunteers.

Authors :
Johansson S
Rosenbaum DP
Palm J
Stefansson B
Knutsson M
Lisbon EA
Hilgendorf C
Source :
British journal of clinical pharmacology [Br J Clin Pharmacol] 2017 Sep; Vol. 83 (9), pp. 2008-2014. Date of Electronic Publication: 2017 May 31.
Publication Year :
2017

Abstract

Aim: Tenapanor (RDX5791/AZD1722), an inhibitor of gastrointestinal Na <superscript>+</superscript> /H <superscript>+</superscript> exchanger NHE3, is being evaluated for the treatment of patients with constipation-predominant irritable bowel syndrome and the treatment of hyperphosphataemia in patients with chronic kidney disease on dialysis. By reducing intestinal H <superscript>+</superscript> secretion, inhibition of NHE3 by tenapanor could indirectly affect H <superscript>+</superscript> -coupled transporter activity, leading to drug-drug interactions. We investigated the effect of tenapanor on the activity of the H <superscript>+</superscript> -coupled peptide transporter PepT1 via assessment of the pharmacokinetics of cefadroxil - a compound transported by PepT1 - in healthy volunteers.<br />Methods: In this open-label, two-period crossover, phase 1 study (NCT02140281), 28 volunteers received in random order: a single dose of cefadroxil 500 mg for 1 day; and tenapanor 15 mg twice daily over 4 days followed by single doses of both cefadroxil 500 mg and tenapanor 15 mg on day 5. There was a 4-day washout between treatment periods.<br />Results: Cefadroxil exposure was similar when administered alone or in combination with tenapanor {geometric least-squares mean ratios [(cefadroxil + tenapanor)/cefadroxil] (90% confidence interval): area under the concentration-time curve 93.3 (90.6-96.0)%; maximum concentration in plasma 95.9 (89.8-103)%}. Tenapanor treatment caused a softening of stool consistency and an increase in stool frequency, consistent with its expected pharmacodynamic effect. No safety concerns were identified and tenapanor was not detected in plasma.<br />Conclusions: These results suggest that tenapanor 15 mg twice daily does not have a clinically relevant impact on the activity of the H <superscript>+</superscript> -coupled transporter PepT1 in humans. This may guide future research on drug-drug interactions involving NHE3 inhibitors.<br /> (© 2017 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)

Details

Language :
English
ISSN :
1365-2125
Volume :
83
Issue :
9
Database :
MEDLINE
Journal :
British journal of clinical pharmacology
Publication Type :
Academic Journal
Accession number :
28432691
Full Text :
https://doi.org/10.1111/bcp.13313